title: Noradrenergic inputs to the paraventricular hypothalamus contribute to hypothalamic-pituitary-adrenal axis and central Fos activation in rats after acute systemic endotoxin exposure.
abstract: Noradrenergic (NA) neurons within the nucleus of the solitary tract (NST) and caudal ventrolateral medulla (VLM) innervate the hypothalamic paraventricular nucleus (PVN) to initiate and modulate hypothalamic-pituitary-adrenal (HPA) axis responses to interoceptive stress. Systemic endotoxin (i.e. bacterial lipopolysaccharide, LPS) activates NA neurons within the NST and VLM that project to the PVN and other brain regions that receive interoceptive signals. The present study examined whether NA neurons with axonal inputs to the PVN are necessary for LPS to activate Fos expression within the PVN and other interoceptive-related brain regions, and to increase plasma corticosterone. Male Sprague-Dawley rats received bilateral stereotaxic microinjections of DSAP (saporin toxin conjugated to an antibody against dopamine-beta-hydroxylase, DbH) into the PVN to destroy NA inputs. Control rats were microinjected with vehicle into the PVN or received no PVN injections. Two weeks later, DSAP and control rats were injected i.p. with LPS (200 microg/kg BW) or saline vehicle, and perfused with fixative 2.5-3 h later. Brain tissue sections were processed to reveal nuclear Fos protein and cytoplasmic DbH immunolabeling. DSAP lesions depleted NA terminals in the PVN and bed nucleus of the stria terminalis, reduced the number of NA cell bodies in the NST and VLM, attenuated PVN Fos activation after LPS, and attenuated LPS-induced increases in plasma corticosterone. These findings support the view that NA projections from hindbrain to hypothalamus are necessary for a full HPA axis response to systemic immune challenge.
authors.affiliation: Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Bienkowski
authors.forename: L
authors.initials: L
authors.lastname: Rinaman
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002243:Carbolines / Q000378:metabolism*; D002452:Cell Count; D003345:Corticosterone / Q000097:blood; D004299:Dopamine beta-Hydroxylase / Q000276:immunology; D004731:Endotoxins / Q000494:pharmacology*; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism*; D000922:Immunotoxins / Q000633:toxicity; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000187:drug effects*; D016761:Oncogene Proteins v-fos / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism*; D010913:Pituitary-Adrenal System / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1 / Q000633:toxicity; D000076985:Saporins; D012686:Septal Nuclei / Q000166:cytology / Q000187:drug effects; D017552:Solitary Nucleus / Q000166:cytology / Q000187:drug effects
chemical_list: D000906:Antibodies; D002243:Carbolines; D004731:Endotoxins; D000922:Immunotoxins; D008070:Lipopolysaccharides; D016761:Oncogene Proteins v-fos; D054789:Ribosome Inactivating Proteins, Type 1; C009804:tryptoline; D004299:Dopamine beta-Hydroxylase; D000076985:Saporins; D003345:Corticosterone
references.citation: J Comp Neurol. 2001 Aug 6;436(4):430-55
references.pmid: 11447588
references.citation: Neuroscience. 1990;39(3):717-25
references.pmid: 2097524
references.citation: Brain Res. 1996 Nov 18;740(1-2):175-84
references.pmid: 8973812
references.citation: J Neurosci. 2000 Sep 1;20(17):6578-86
references.pmid: 10964963
references.citation: J Comp Neurol. 1995 Sep 18;360(2):246-56
references.pmid: 8522645
references.citation: Brain Behav Immun. 2004 Mar;18(2):123-34
references.pmid: 14759590
references.citation: J Neurosci. 2003 Nov 5;23(31):10084-92
references.pmid: 14602823
references.citation: J Neurosci. 1994 Feb;14(2):897-913
references.pmid: 8301368
references.citation: Exp Neurol. 1988 Oct;102(1):121-4
references.pmid: 2846338
references.citation: Am J Physiol. 1999 Oct;277(4):R1063-75
references.pmid: 10516246
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2359-64
references.pmid: 8637878
references.citation: Neuroscience. 1997 Aug;79(4):1165-75
references.pmid: 9219975
references.citation: J Comp Neurol. 2007 May 20;502(3):455-67
references.pmid: 17366612
references.citation: Brain Res. 2007 Jan 26;1130(1):130-45
references.pmid: 17169348
references.citation: Psychoneuroendocrinology. 2003 Jan;28(1):19-34
references.pmid: 12445834
references.citation: Physiol Rev. 1999 Jan;79(1):1-71
references.pmid: 9922367
references.citation: J Neurosci. 2006 Nov 1;26(44):11442-53
references.pmid: 17079674
references.citation: Am J Physiol. 1999 Aug;277(2):R582-90
references.pmid: 10444567
references.citation: J Comp Neurol. 1996 Oct 21;374(3):315-31
references.pmid: 8906501
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R751-9
references.pmid: 16627690
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Oct;291(4):R870-9
references.pmid: 16675637
references.citation: FEBS Lett. 1992 Feb 24;298(2-3):145-8
references.pmid: 1544437
references.citation: J Comp Neurol. 1982 Mar 1;205(3):260-72
references.pmid: 6122696
references.citation: Peptides. 1986 Jan-Feb;7(1):155-9
references.pmid: 3520509
references.citation: J Comp Neurol. 1998 Apr 6;393(2):244-66
references.pmid: 9548700
references.citation: Endocrinology. 2003 Apr;144(4):1357-67
references.pmid: 12639919
references.citation: J Comp Neurol. 2001 Apr 2;432(2):197-216
references.pmid: 11241386